N umerous patients undergoing anesthesia have an accompanying disease that is often treated with corticosteroids. Accordingly, during anesthesia, they need to receive substitution therapy (e.g., hydrocortisone) to avoid intraoperative adrenal insufficiency. In addition, prophylactic corticosteroids are often administered during surgery to attenuate the inflammatory response to surgical trauma. 1 Furthermore, corticosteroids remain one of the first-line drugs in the treatment of reactive airways disease, anaphylaxis (e.g., hydrocortisone, methylprednisolone), septic shock (e.g., hydrocortisone), and laryngeal, cerebral, and surgical edema, 2 as well as in combination in multimodal analgesia 3, 4 and for prevention of postoperative nausea and vomiting. [5] [6] [7] Dexamethasone is frequently used for the last 3 indications, and structurally, it closely resembles the aminosteroid neuromuscular-blocking drugs. Recently, concerns have been raised about possible interactions between corticosteroids and the first selective relaxant binding drug, sugammadex.
In the early in vitro studies by Zhang, 8 isothermal titration calorimetry showed that >40 lipophilic, steroid, and nonsteroid drugs have some potential for interactions with sugammadex, although these affinities were 120-fold to 700-fold lower than that for the aminosteroid neuromuscular-blocking drug rocuronium. The same BACKGROUND: Corticosteroids are frequently used during anesthesia to provide substitution therapy in patients with adrenal insufficiency, as a first-line treatment of several life-threatening conditions, to prevent postoperative nausea and vomiting, and as a component of multimodal analgesia. For these last 2 indications, dexamethasone is most frequently used. Due to the structural resemblance between aminosteroid muscle relaxants and dexamethasone, concerns have been raised about possible corticosteroid inhibition in the reversal of neuromuscular block by sugammadex. We thus investigated the influence of dexamethasone on sugammadex reversal of rocuronium-induced neuromuscular block, which could be relevant in certain clinical situations. METHODS: The unique co-culture model of human muscle cells innervated in vitro with rat embryonic spinal cord explants to form functional neuromuscular junctions was first used to explore the effects of 4 and 10 μM rocuronium on muscle contractions, as quantitatively evaluated by counting contraction units in contraction-positive explant co-cultures. Next, equimolar and 3-fold equimolar sugammadex was used to investigate the recovery of contractions from 4 and 10 μM rocuronium block. Finally, 1, 100, and 10 μM dexamethasone (normal, elevated, and high clinical levels) were used to evaluate any effects on the reversal of rocuronium-induced neuromuscular block by sugammadex. RESULTS: Seventy-eight explant co-cultures from 3 time-independent experiments were included, where the number of contractions increased to 10 days of co-culturing. Rocuronium showed a time-dependent effect on depth of neuromuscular block (4 μM rocuronium: baseline, 10, 20 minutes administration; P < 0.0001), while the dose-dependent effect was close to nominal statistical significance (4, 10 μM; P = 0.080). This was reversed by equimolar concentrations of sugammadex, with further and virtually complete recovery of contractions with 3-fold equimolar sugammadex (P < 0.0001). Dexamethasone diminished 10 μM sugammadex-induced recovery of contractions from rocuronium-induced neuromuscular block in a dose-dependent manner (P = 0.026) with a higher sugammadex concentration (30 μM) being close to statistically significantly improving recovery (P = 0.065). The highest concentration of dexamethasone decreased the recovery of contractions by equimolar sugammadex by 26%; this effect was more pronounced when 3-fold equimolar (30 μM) sugammadex was used for reversal (48%). CONCLUSIONS: This is the first report in which the effects of rocuronium and sugammadex interactions with dexamethasone have been studied in a highly accessible in vitro experimental model of functionally innervated human muscle cells. Sugammadex reverses rocuronium-induced neuromuscular block; however, concomitant addition of high dexamethasone concentrations diminishes the efficiency of sugammadex. Further studies are required to determine the clinical relevance of these interactions. (Anesth Analg 2014;118:755-63) ANesthesiA & ANAlgesiA method was used in a recent study of Zwiers et al., 9 where 300 drugs were tested and modeled to determine possible drug interactions with sugammadex. Of all the tested compounds, only 3 were considered possible for the displacement of rocuronium from sugammadex under clinical conditions: toremifene, fusidic acid, and flucloxacilline. 9, 10 According to these model-based chemical studies and the theoretical molecular features, sugammadex appears to be highly selective for aminosteroid neuromuscular-blocking drugs, with the minimal possibility of interactions with other drugs. However, our clinical experience in patients receiving sugammadex shortly after high-dose (> 0.3 mg/kg) dexamethasone, where the reversal appeared to be prolonged, does not support this. Furthermore, our recent preclinical study demonstrated that in an in vitro model of co-cultured human muscle cells innervated with rat embryonic spinal cord explants that form de novo functional neuromuscular junctions, addition of dexamethasone in combination with sugammadex diminished dexamethasone-induced decreases in functional innervation and constitutive interleukin 6 secretion. 11 Therefore, the aim of the present study was to investigate this particular interaction between dexamethasone and sugammadex in an in vitro model based on the co-culturing of human skeletal muscle cells with rat spinal cord explants. This system is readily accessible and serves as a good model for studying the functional (physiological) effects of drugs (molecules) with direct or indirect targets at the neuromuscular junction by assessing the efficiency of neuromuscular transmission. 
METHODS

Co-cultures of Human Muscle Cell Explants and Rat Embryonic Spinal Cord Explants
Innervated human muscle cell cultures were prepared as previously described. [12] [13] [14] [15] Primary human myoblast cell cultures were derived from satellite cells that were released from the excess muscle tissue that was obtained from patients who underwent orthopedic surgery and had given informed consent. These patients had no diagnosed neuromuscular diseases. To obtain the human muscle satellite cells, the human muscle tissue was separated from connective tissue, dissected into 0.5 to 1.0 mm pieces, and trypsinized. The muscle satellite cells were then grown to clonal density in 100-mm Petri dishes in advanced minimal essential medium (aMEM, Invitrogen Gibco, Paisley, UK) containing 10% (vol/vol) fetal bovine serum (FBS), 100 mM vitamin solution, 10 mM nonessential aminoacids, 110 mg/L sodium pyruvate, 200 mg/L GlutaMAX, 0.3% (vol/vol) fungizone, and 0.15% (vol/vol) gentamicin (all obtained from Invitrogen, Paisley, UK) at saturating humidity in a mixture of 5% CO 2 and air at 37°C. Morphologically identified myoblast colonies were cleared of fibroblast contaminants and trypsinized for further development in aMEM with 10% FBS. Confluent myoblast cultures were again trypsinized before myoblast fusion and placed on glass coverslips coated with a 1:2 mixture of 1.5% gelatin (Sigma-Aldrich, St. Louis, MO) and human serum, in 35-mm 6-well dishes. Subsequently, myoblast cultures were grown in F14 medium (Invitrogen) supplemented with 10% FBS, 50 ng/mL fibroblast growth factor, 10 ng/mL epidermal growth factor, and 10 μg/mL insulin (all from Sigma-Aldrich). Timed pregnant Wistar rats were killed at 14 days from gestation in a CO 2 chamber (as approved by the Veterinary Administration of the Ministry of Agriculture and the Environment; permit number 323-02-74/00) to isolate embryonic neural tissue. All efforts were made to limit the number of animals used, as well as their suffering. After the myotubes formed from the myoblasts, up to 4 segments of dissected spinal cord explants with preserved anatomical connections to dorsal root ganglia and preserved meninges were placed on the myotube monolayers. Over the following 7 to 10 days, these explant co-cultures were cultivated in F14 medium with 5% (vol/vol) FBS and 10 μg/mL insulin, which was refreshed every 2 to 3 days. Their functional innervation was microscopically quantified by counting the number of contracting units (CUs) in the proximity of the spinal cord explant (area of innervation) in the co-cultures. A CU was defined by the simultaneous contraction of a distinct group of muscle fibers at their specific frequency, which occurred at different CU frequencies across the explant preparations, as previously described. [14] [15] [16] Experiments were conducted when the number of contraction-positive co-cultured explants reached a steady state.
The experiments were performed in 3 time-independent sets of explant co-cultures that were prepared from 3 different donors, with the spinal cord explants isolated from 3 different experimental animals to avoid any possible influence of biological variance and to suffice the criteria for statistical analysis. All the CU counts were assessed by the same person, blinded to the experimental conditions and experienced in observing these explant co-cultures, to avoid bias and interobserver variability.
Treatment with Rocuronium, Dexamethasone, and Sugammadex
We initially compared the effects of 2 different final concentrations of rocuronium bromide (4 and 10 μM; Esmeron, NV Organon, BH OSS, The Netherlands) on the muscle contraction of the explant co-cultures, to determine the rocuronium concentration that induced their complete neuromuscular block (NMB). The induction of NMB was quantitatively evaluated by continuous observation under an inverted microscope (Olympus IX81F, Tokyo, Japan), with the counting of the number of CUs per explant 14 at the 2 time points of 10 and 20 minutes after the addition of rocuronium. This rocuronium-induced NMB was then reversed by the addition of equimolar sugammadex (i.e., 4 and 10 μM sugammadex added to 4 and 10 μM rocuronium, respectively).
Subsequent experiments were performed with the higher concentration of rocuronium (10 μM). In parallel explant cocultures, which included dexamethasone-untreated control explant co-cultures and explant co-cultures where 1, 100, and 10 μM dexamethasone (final concentrations) were added along with 10 μM rocuronium with 10 μM sugammadex (final concentration, equimolar with rocuronium) or 30 μM sugammadex (final concentration; i.e., 3 × equimolar with rocuronium). Appropriate volumes of stock solution needed to reach the desired final concentrations of rocuronium, sugammadex, and dexamethasone were added directly to the culture medium, followed by gentle mixing. Under all these treatment conditions, the CUs were determined after 5 minutes of incubation, unless stated otherwise.
For the comparisons across the individual explant preparations, the data are expressed as the individual and mean numbers of CUs per explant, as indicated. For the combined data across explant co-cultures for the dexamethasone effects on the sugammadex reversal of the rocuronium NMB, the data are expressed as the mean ratios of the number of CUs with rocuronium (10 μM) plus sugammadex (10, 30 μM) addition versus the initial number (baseline) of CUs before the active treatments, without and with dexamethasone addition, as indicated. Of note, in the calculation of these ratios, 0.5 was added to each CU count to allow for zero counts at baseline. This can also be justified substantially because it is the approximate proportion of "noise" in an observation, in the sense of the contractions observed in the fibers that had initially not contracted.
Statistical Analysis
The effects of rocuronium and sugammadex on contractions were first tested by using pairwise Wilcoxon signed-rank tests (exact version). In addition, 2-way mixed model analysis of variance (ANOVA) was used with time as the within-subjects factor (3 levels) and rocuronium or sugammadex concentrations as between-subjects factor (2 levels). To compare the control group (i.e., 10 μM rocuronium plus 10 μM sugammadex without dexamethasone) with the addition of equimolar (10 μM) dexamethasone, the ratios of active treatment versus baseline were compared by using the exact version of the Mann-Whitney test. To test the effects of the different additions of dexamethasone (1, 100, and 10 μM), the exact version of the Kruskal-Wallis test was used, while the pooled effect of 2 final concentrations of sugammadex (10 and 30 μM) on the recovery of contractions was tested by using the exact version of the Wilcoxon signed-rank test. Statistical significance was set at P ≤ 0.05 (P values between 0.05 and 0.10 were also given substantial consideration because of the small sample size). All the statistical tests were 2-sided. Statistical analyses were performed by using IBM SPPS Statistics 20.0 for Windows (IBM Corp., Armonk, NY).
It should be noted that a potential threat to the statistical assumption of independence of observations could be that segments of spinal cord explants (2 to 4) were added to myoblast cultures previously formed in 6-well dishes, meaning that those contracting muscle fibers that were innervated by the same spinal cord explants are probably more similar to each other than contracting muscle fibers among different spinal cord explants (or even different wells), but they have been treated as independent in all previous related studies. There are also clear substantial (physiological and biochemical) reasons for treating the contraction units as independent.
RESULTS
Evaluation of Co-cultures
In agreement with previous studies, 14, 15 the first extensions of neuritis from the spinal cord explants were seen after 1 to 2 days from the setup of these explant co-cultures, and the first contractions were seen after 7 days (Fig. 1 ). The number of contraction-positive explant co-cultures increased up to 10 days of co-culturing (as described in the Methods section). Altogether, 78 contraction-positive explant co-cultures were pooled and included in the statistical analysis. In the data presented in this study, there was an initial mean of 1.45 (SD 1.46) CU per explant co-culture.
Effects of Rocuronium and Sugammadex
In these co-cultures of human muscle cells and embryonic rat spinal cord explants, 10-minute rocuronium treatment showed dose-dependent effects on the depth of NMB obtained, with 10 μM rocuronium significantly increasing NMB (Figs. 2 and 3) . At 4 μM rocuronium, this response was also time-dependent, showing a further significant increase in NMB at 20 minutes of treatment ( Figs. 2 and 3 ). However, with 10 μM rocuronium, there was virtually complete cessation of contractions (NMB) after 10 minutes, which did not change further with time (Figs. 2 and 3; 20 minutes). ANOVA indicated that the effect of time (baseline, 10, 20 minutes) was statistically significant (P < 0.0001); the effects of rocuronium concentration (4, 10 μM; P = 0.080) were close to nominal statistical significance, whereas the interaction effect was not statistically significant (P = 0.102).
Minimal reversal of the 4 μM rocuronium NMB was achieved by the addition of equimolar (4 μM) sugammadex, whereas at 10 μM rocuronium, there appeared to be a more pronounced effect of the equimolar (10 μM) sugammadex on NMB reversal ( Figs. 3 and 4 ). When the sugammadex concentration was further increased to 3 × equimolar (12, 30 μM, respectively), there was a further ANesthesiA & ANAlgesiA small reversal of the NMB that appeared to be larger in the explant co-cultures treated with 10 μM rocuronium ( Figs. 3 and 4 ). ANOVA indicated that the overall effect of sugammadex concentration was statistically significant (P < 0.0001), with no statistically significant effects of either rocuronium concentration (P = 0.249) or the interaction (P = 0.577).
Effects of Dexamethasone on Sugammadex-Induced Recovery of Contractions From Rocuronium NMB
When assessing the effects of 10 μM dexamethasone addition on (10 μM) sugammadex-induced recovery of contractions from (10 μM) rocuronium NMB (the equimolar rocuronium/ sugammadex control), we observed a higher ratio of the number of CUs in the equimolar rocuronium/ sugammadex control to the number of initial (i.e., baseline) CUs without 10 μM dexamethasone addition (median 1.00, interquartile range 0.68-1.00) as compared with the 10 μM dexamethasone-treated cultures (median 0.51, interquartile range 0.05 to 1.00; Fig. 5A ), though the difference between the 2 groups did not reach statistical significance (P = 0.089 from Mann-Whitney test). Similarly, a difference was also observed when the data were examined according to the numbers of CUs per explant co-culture ( Fig. 5B ), whereby the difference between the 2 groups did not reach statistical significance (P = 0.074 from Mann-Whitney test). The observed decrease in the mean ratio of the number of CUs to the number of initial CUs by 10 μM dexamethasone in comparison with the equimolar rocuronium/sugammadex control was by 26%; the observed difference between the 2 groups was even more pronounced when 3-fold equimolar (30 μM) sugammadex was used for reversal (it was by 48%).
The effects of different concentrations of dexamethasone on the equimolar (10 μM) and 3-fold equimolar (30 μM) rocuronium/sugammadex reversal of contractions are summarized in Figure 6 . Compared with the baseline CU count, the number of CUs increased, although not statistically significantly (P = 0.092 from Mann-Whitney test), after 10 μM sugammadex with the initial concentration of dexamethasone (1 nM). The ratio was then statistically significantly reduced in a dose-dependent manner by 100 nM and 10 μM dexamethasone (P = 0.026 from Kruskal-Wallis test). An increase in the concentration of sugammadex (30 μM) in the co-culture medium produced a similar pattern (P = 0.020 from Mann-Whitney test for comparison of the CU count after sugammadex against baseline with the initial concentration of dexamethasone and P = 0.034 from Kruskal-Wallis test for the dexamethasone-dose-dependent reduction in the ratio of CU count to baseline), whereby it was close to statistically significantly improving the reversal of rocuronium-induced NMB in the 3 dexamethasone groups pooled (P = 0.065 from Wilcoxon signed rank test).
CONCLUSIONS
In the present study, conducted in an in vitro explant co-culture model of innervated human muscle cells, we demonstrated complete rocuronium NMB that was reversed by equimolar concentrations of sugammadex. The NMB and its reversal were more effective when higher doses of rocuronium and sugammadex were used. Furthermore, we observed that dexamethasone diminished the reversal of rocuronium-induced NMB by sugammadex in a dose-dependent manner, with a peak effect achieved at the high clinical concentration of 10 μM dexamethasone.
To our knowledge, this is the first report in which the effects of rocuronium and sugammadex and the interaction with dexamethasone have been studied in co-cultures of human muscle cells and embryonic rat spinal cord explants. www.anesthesia-analgesia.org
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We believe that the unique and accessible experimental model of functional innervation is an advanced approach in comparison with methods used in previous in vitro studies. Furthermore, this is a biological model of functionally innervated human muscle cells that provides improved in vitro conditions to simulate the actual in vivo conditions compared with chemical-based models for the analysis of drug interactions, such as those used in the studies of Zhang 8 and Zwiers et al. 9 The concentrations for rocuronium and sugammadex used in our study were chosen based on previous in vitro studies, [17] [18] [19] [20] [21] performed mainly on an isolated rat phrenic nerve (hemi) diaphragm preparation, as first described by Bülbring. 22 These are essentially within the wide range of plasma concentrations of both drugs in anesthetized patients. [23] [24] [25] [26] [27] However, animal and human studies where the more sophisticated microdialysis method was used have shown that rocuronium concentrations in interstitial fluid are mainly lower than the concentrations used in our model. 28, 29 The concentrations of dexamethasone correspond to baseline (1 nM) and elevated (0.1 μM) endogenous cortisol concentrations that have been observed in normal and septic patients, respectively. 30 In our recent clinical study, we observed that the administration of 0.15 mg/kg dexamethasone resulted in plasma concentrations up to 4.5 μM within 10 minutes after IV administration (unpublished data). However, a study on the pharmacokinetics of single high doses of dexamethasone (1.66 to 2.49 mg/kg) in cancer patients revealed that here its plasma concentrations can be much higher and can reach levels well above 10 μM in the first hour. 31 Such high doses are used during anesthesia as well, for instance in cardiac surgery. 1, [32] [33] [34] [35] Nevertheless, we believe that 10 μM dexamethasone mainly represents a supratherapeutic concentration, yet in certain groups of patients, it can be reached. Therefore, by using 3 different concentrations of dexamethasone, we covered a wide span of possible plasma concentration that can be encountered in patients undergoing anesthesia.
In our explant co-culture model system, 4 μM rocuronium failed to produce complete NMB after 10 minutes of exposure, in contrast to previous studies, 21 whereas 10 μM rocuronium provided complete NMB. This is in agreement with the well-known concept that, in general, higher concentrations of drugs are needed to exert their effects under in vitro conditions. We then observed the almost complete reversal of the rocuronium NMB by equimolar concentrations of sugammadex, at both 4 and 10 μM rocuronium, with the reversal at the higher rocuronium concentration (10 μM) more effective when sugammadex was 3-fold equimolar (30 μM) to rocuronium, which correlates well with previous studies. 19, 21, 36 This experimental pharmacological interaction between rocuronium and sugammadex thus represents the in vitro simulation of what would be expected under clinical in vivo conditions.
According to the effects of the interactions between specific substances and sugammadex, 2 types of interactions can occur: displacement and capturing. In our previous study that was performed in an in vitro model of innervated human muscle cells, we showed that binding between dexamethasone and sugammadex can result in reduced dexamethasone effects on functional innervation and constitutive interleukin 6 secretion. 11 However, in the present study, we examined the dexamethasone displacement of rocuronium from its binding site in sugammadex, thus making sugammadex less available for reversal of the NMB. This was previously addressed in a study of Zwiers et al., 9 where a pharmacokinetic-pharmacodynamic model was used to investigate the displacement interactions of sugammadex with numerous drugs, whereby dexamethasone showed the lowest association rate constant among the corticosteroids tested. 9 This indicated that the displacement of aminosteroid neuromuscular-blocking drugs from sugammadex by using dexamethasone would be virtually impossible. Corticosteroids indeed lack the charged quaternary nitrogen on the ammonium group of NMB drugs that binds to the carboxyethyl side chains of sugammadex; moreover, corticosteroids are highly bound by plasma proteins, especially the albumins, that makes them less available for binding to sugammadex. 37 The total protein concentration in culture medium achieved by using the standard percentage of serum (FBS) is lower than the total protein concentration in human plasma or interstitial fluid. This might affect the protein binding and the availability of free dexamethasone and should therefore be taken into consideration when interpreting dexamethasone's dose-dependent effects on reversal of rocuronium-induced NMB by sugammadex. With this in mind, the data from our previous study 11 and the present study provide the validation of a biological experimental system that now seriously challenges the findings of Zwiers et al. 9 Indeed, this biological system demonstrates that in co-cultures of human muscle cells and embryonic rat spinal cord explants, dexamethasone can diminish the efficiency of sugammadex. However, it is important to stress that the high level of dexamethasone where the reversal of rocuroniuminduced NMB with sugammadex was clearly compromised (10 μM) might be achieved clinically only shortly after IV administration of high dose of dexamethasone in humans; this dexamethasone will then undergo rapid distribution to peripheral compartments, such that the concentrations of dexamethasone in the plasma will remain much lower. An increase in the amount of sugammadex improved reversal of rocuronium-induced NMB, although the reversal remained incomplete under the highest dexamethasone condition. Therefore, it appears that with the highest dexamethasone concentration, its binding to sugammadex is difficult to overcome even with a surplus of sugammadex.
In addition, the low displacement potential of dexamethasone 9 allows us to extrapolate the results of the present study to other corticosteroids. For instance, betamethasone has the highest association rate constant with sugammadex (higher than flucloxacilline), 9 and therefore, we would predict its interaction with sugammadex in a similar concentration range as dexamethasone, which in clinical terms might delay recovery from NMB or cause reoccurrence of NMB.
The present findings, however, should be interpreted taking into consideration the limitations of the study. Although the neuromuscular junctions in our in vitro model are morphologically and physiologically highly developed, our results cannot be completely translated into in vivo clinical conditions. First, since these are de novo neuromuscular junctions, their performance could, to some extent, differ from those in vivo. Muscle cell contractions indicate functional neuromuscular junction transmission, and although the strength of such contractions can be assessed to some extent, 38, 39 it would be rather difficult to extrapolate these findings to in vivo situation; in this model, we observe contractions of individual muscle fibers and not skeletal muscle as a whole. Second, while we endeavored to achieve analog concentrations of drugs to those in the sera of treated patients, along with correspondingly lower amounts of protein in the co-culture medium, the exact binding, and thus the availability, of dexamethasone in comparison with clinical conditions remains questionable. Third, the combination of time of dexamethasone administration and achievement of its maximal concentration in patient's serum will probably be critical to observe any effects on sugammadex reversal. Fourth, the lack of other (unidentified) systemic factors could contribute to different outcomes in vivo compared with those observed herein. Finally, although we strove to avoid the influence of biological variability and observer bias, it was impossible to completely eliminate these 2 factors, which could have Figure  6 . Dexamethasone effects on sugammadex reversal of rocuronium-induced neuromuscular block (NMB). Comparison between the equimolar (10 μM) and 3-fold equimolar (30 μM) sugammadex/rocuronium with 1 (N = 12), 100 nM (N = 15) and 10 μM dexamethasone (N = 9), as indicated. The data are expressed as the ratio of the number of contracting units (CUs) of the equimolar (10 μM) and 3-fold equimolar (30 μM) sugammadex/rocuronium control without and with dexamethasone versus the number of initial (control baseline) CUs. The dashed line represents the ratio where the rocuronium-induced NMB would be completely reversed by sugammadex.
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ANesthesiA & ANAlgesiA altered the results. However, the data acquired throughout multiple observations under such unique experimental conditions dictated the use of data transformations, and the statistical tests were chosen as a compromise between optimality and understandability for a clinical audience.
In conclusion, dexamethasone does not appear to decrease the efficiency of sugammadex during the reversal of rocuronium-induced NMB when used in nanomolar concentration range. However, our data also suggest that micromolar concentrations of dexamethasone significantly suppress sugammadex's action, indicating that high-dose dexamethasone therapy during surgery may lead to the clinically relevant interactions with sugammadex during the reversal of NMB. Clearly, such inferences from an in vitro model need to be confirmed in the clinical setting. Finally, it is important to stress that sugammadex has brought substantial progress into clinical anesthesia, and even if suppression of sugammadex's action during high-dose dexamethasone therapy is confirmed in a clinical study, it will undoubtedly remain a mainstay in the reversal of rocuronium-induced NMB under most clinical conditions. E
